ESSEN/MUNICH, Germany, September 9, 2025 – Evonik and Ethris have entered a strategic partnership to enhance RNA-based therapeutic solutions by developing and manufacturing advanced lipid nanoparticle delivery systems. The collaboration focuses on accelerating innovation in respiratory diseases and other conditions, offering novel formulations that provide greater stability, precise targeting, and scalable clinical manufacturing.
Science Significance
The collaboration brings together Ethris’ SNaP LNP technology with Evonik’s expertise in lipid formulation and process development. This integration is expected to lead to improvements in thermostability, allowing formulations to be stored at higher temperatures without compromising effectiveness. It also enhances local retention of therapeutics, reducing the need for repeated dosing while increasing drug efficacy at target sites.
In clinical validation, nebulized delivery of RNA therapeutics demonstrated no systemic bioavailability, meaning the active molecules act locally within the lungs, minimizing the risk of side effects. This approach opens the door to treating diseases such as asthma, chronic obstructive pulmonary disease, and other respiratory conditions, providing an alternative to systemic treatments.
Regulatory Significance
The partnership aligns with the growing regulatory focus on ensuring safe and effective delivery systems for nucleic acid medicines. The combined expertise strengthens the foundation for clinical studies that meet stringent safety and quality standards required for approval by authorities worldwide.
Advertisement
With ongoing trials already generating encouraging data, the partnership aims to fast-track development, enabling expedited regulatory pathways and accelerating the availability of innovative treatments to patients in need.
Business Significance
The global lipid nanoparticle market, projected to reach US$2.3 billion by 2032, presents significant opportunities for growth. By leveraging Evonik’s CDMO capabilities and Ethris’ proprietary technology, the partnership aims to address the increasing demand for precision medicines and targeted drug delivery.
This collaboration is positioned to expand into new markets, create high-value jobs, and establish a leadership position in RNA therapeutics, especially for rare diseases and chronic respiratory conditions.
Patients’ Significance
For patients, particularly those suffering from chronic lung diseases, this partnership offers a more effective and safer treatment option. The localized action of RNA therapeutics helps reduce unwanted side effects while improving the efficiency of drug delivery.
By offering nebulized formulations, the treatment could become less invasive and more accessible, improving adherence and enhancing the overall quality of life for individuals requiring long-term care.
Policy Significance
This collaboration reflects the importance of regulatory frameworks that encourage biotech innovation while safeguarding patient safety. By advancing nucleic acid medicines, the partnership supports policy initiatives aimed at broadening treatment access, reducing healthcare disparities, and fostering public-private cooperation in medical research and development.
The Evonik and Ethris partnership represents a critical advancement in the field of RNA therapeutics. By combining proprietary lipid nanoparticle technology with cutting-edge formulation expertise, the collaboration is poised to transform treatment options for respiratory diseases and beyond.
With a focus on stability, targeting, and scalability, this partnership is set to reshape the future of precision medicine, offering new hope to patients and strengthening global efforts to address some of the most complex healthcare challenges.
Source: Evonik Industries AG Press Release
